We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




First Mobile Diagnostic System Performs Instant Lab Quality Blood Analysis Anywhere

By LabMedica International staff writers
Posted on 25 Aug 2023

Presently, the complete blood count (CBC) is one of the most frequently recommended diagnostic tests to evaluate an individual's overall health by measuring factors like oxygen-transporting red blood cells, infection-combating white blood cells, and blood-coagulating platelets. More...

However, there are issues with CBC testing such as patient expenses, accessibility, and time consumption. Patients require a referral, followed by scheduling a nurse appointment for blood collection. This is followed by waiting in the clinic, and sometimes waiting for hours or days after the blood draw to obtain the results. Moreover, a substantial portion of the global population lacks access to proper diagnostics due to distance from clinics or financial constraints. Now, a groundbreaking diagnostic system is making waves in the point of care (POC) setting, offering the first mobile technology for instant blood analysis beyond the confines of a lab. This innovation has the potential to bring lab tests within reach of millions worldwide.

The REVDX from EFA Technologies (Caesarea, Israel) is a portable lab-quality device that incorporates advanced multi-channel technology. This handheld device can be used anywhere, eliminating the need for time-consuming preparations or specialized knowledge. It is mobile, portable, and handheld, capable of functioning without electricity or internet connectivity, while also being cost-effective. At present, the device can conduct a blood count, with plans for additional tests in the future. A simple finger prick is all that's required, eliminating the need to visit a lab and delivering results in just minutes. The device aims to empower doctors and medical teams in diverse scenarios to make informed treatment decisions promptly, bypassing the wait time for blood tests and their subsequent results. The REVDX is user-friendly, operating via a finger prick and independent of elaborate lab conditions or specific preparations.

In patients with fever, the most critical test to conduct is a CBC. These results can assist in administering antibiotics for suspected bacterial infections, avoiding unwarranted antibiotic use in viral infections, and identifying parasitic infections like malaria. Presently, most labs provide CBC results within 24 to 72 hours, with a significant time lapse during test transportation. The absence of real-time blood count data contributes to antibiotic overuse, which exacerbates antimicrobial resistance (AMR). REVDX has the capability to conduct automated microscopy tests, encompassing full blood sampling and immediate full blood count diagnosis. Physicians can utilize REVDX to make real-time, informed judgments about the likelihood of a bacterial infection, curtailing unnecessary antibiotic use. This positions REVDX as an indispensable device for every point of need across the world.

Related Links:
EFA Technologies 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Neurofilament Light Chain Assay
Lumipulse G NfL Blood
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Study design and workflow (Parankusham H, Vanderlip C, Birkenbihl C, et al. A two-stage plasma biomarker algorithm reduces amyloid PET use and the p-Tau217 gray zone. Annals of Clinical and Translational Neurology. Published online October 19, 2026. doi:10.1002/acn3.70560)

Two-Step Blood Testing Approach Reduces Uncertainty in Amyloid Assessment

Blood-based biomarkers offer a more accessible, less expensive way to detect Alzheimer’s-related brain changes than traditional methods such as amyloid-beta positron emission tomography (Aβ-PET).... Read more

Molecular Diagnostics

view channel
Image: Tumor DNA is extracted from a pathology sample, and normal DNA is extracted from the buffy coat. Both samples undergo WGS to generate the patient-specific mutational signature. At each follow-up, ctDNA extracted from plasma undergoes WGS and is analyzed using a patient-derived signature and an artificial intelligence (AI) pattern recognition algorithm. FFPE: formalin fixed, paraffin embedded. (Snuderl M, Smadbeck J, Wilkins R, et al. The Journal of Molecular Diagnostics, 2026. DOI: 10.1016/j.jmoldx.2026.07.003)

Liquid Biopsy Detects Lung Cancer Recurrence Signals Months Before Imaging

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and remains a major cause of cancer-related death. Early-stage tumors are often treated surgically, but recurrence can still occur... Read more

Immunology

view channel
Image Credit: iStock

Antibody Profiling Predicts Inflammatory Bowel Disease Years Before Diagnosis

Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, involves abnormal immune responses that cause persistent inflammation and damage in the digestive system.... Read more

Pathology

view channel
Image: HETA Quality Control identifies slide quality issues before analysis, while HETA Tumor Detect annotates tumor regions and flags slides likely to contain tumor during scanning. (Photo courtesy of Aignostics)

AI Pathology Platform Targets Workflow Delays and Molecular Test Failures

Pathology laboratories often rely on visual review of tissue slides to assess quality, identify tumors, count mitoses, and estimate tumor content. These tasks can be time-consuming and vary between readers,... Read more

Technology

view channel
Image: Signals LabGistics uses AI to turn natural-language instructions and SOPs into coordinated scientific workflows, helping connect teams, systems, and processes. (Photo courtesy of Revvity)

New AI-Powered System Aims to Streamline Laboratory and Manufacturing Workflows

Scientific laboratories supporting drug development, biotechnology, and materials research increasingly rely on coordinated digital workflows to move data, samples, and activities across teams.... Read more

Industry

view channel
Image: The acquisition of Reveal Genomics would expand Hologic’s oncology diagnostics portfolio to support treatment decisions for more women with breast cancer.

Hologic to Broaden Breast Cancer Testing Portfolio Through Reveal Genomics Acquisition

Hologic (Marlborough, MA, USA) has signed a definitive agreement to acquire Reveal Genomics (Barcelona, Spain), a precision oncology company developing genomic diagnostic tests to help personalize cancer treatment.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.